Primerica (NYSE: PRI) Q3 2025 beats: EPS $6.35; revenue $839.9M; record $3.7B ISP sales as investors eye today’s earnings call

6 November 2025

Published November 6, 2025

DULUTH, Ga. — Primerica (NYSE: PRI) posted stronger‑than‑expected third‑quarter 2025 results after Wednesday’s close, setting fresh records in its Investment & Savings Products (ISP) business and topping Wall Street’s earnings and revenue forecasts ahead of its conference call this morning (10:00 a.m. ET, Nov. 6). Total revenue rose 8% year over year to $839.9 million, while GAAP EPS came in at $6.35 and diluted adjusted operating EPS at $6.33, up 11% from a year ago. Management also highlighted record ISP sales of $3.7 billion and quarter‑end client asset values of $126.8 billion. ^[1]

Zacks/ Yahoo Finance calculated a +14.7% EPS surprise and ~+1.4% revenue surprise versus consensus, underscoring the beat. A Reuters earnings‑preview the day before had primed investors for $5.53 EPS and about $823.5 million in revenue, both of which the company exceeded. ^[2]

Key takeaways

Revenue & earnings: Revenue $839.9M (+8% YoY); GAAP EPS $6.35; adjusted operating EPS $6.33 (+11% YoY). ^[3]
Street vs. actual: EPS beat by roughly +14–15%; revenue beat by ~+1–2% vs. consensus. ^[4]
Distribution engine:Life‑licensed sales force 152,200 (+2% YoY), even as recruits (−29%) and new licenses (−13%) normalized from last year’s unusually strong levels. ^[5]
Term Life:Adjusted direct premiums +5%; segment revenue +3%; pre‑tax operating income −3% (includes remeasurement gain; see below). ^[6]
Investment & Savings Products:Record sales $3.7B (+28%); segment revenue +20%; client asset values +14%; net inflows $363M (vs. $255M a year ago). ^[7]
Capital returns:$129M of share repurchases in Q3; dividend $1.04 per share payable Dec. 15, 2025 (record date Nov. 21, 2025). RBC ratio ~515% as of Sept. 30. ^[8]

What drove the beat

Primerica’s outperformance was powered by a two‑engine story:

ISP momentum stayed hot. Favorable markets, steady net inflows, and a healthier mix (e.g., variable annuities, U.S. managed accounts, Canadian mutual funds under the principal‑distributor model) pushed asset‑ and sales‑based commissions higher than asset growth itself. ^[9]
Term Life remained steady on premiums, even as productivity and issued policy counts cooled from last year’s peak comparisons. The benefits & claims ratio ticked up to 54.9% (from 53.2% YoY), while DAC amortization and insurance expense ratios held largely stable. ^[10]

One‑time actuarial effects to note

As part of its annual assumption review, Primerica recorded a net remeasurement gain of $23.1M (≈$0.54 per diluted share) in Q3, versus $23.0M (≈$0.52) in the prior‑year period. Management also reported adjusted operating figures to strip out such items: adjusted operating revenue $838.9M and adjusted net operating income $206.1M, both growing solidly YoY. ^[11]

Street setup and how results compared

Ahead of the report, LSEG/Reuters’ tally pointed to $5.53 EPS and ~$823.5M in revenue. The company cleared both hurdles, and third‑party recaps this morning echo the beat and the record ISP prints. ^[12]

Independent write‑ups also flagged the initial positive share reaction immediately after the release, while broader summaries emphasized the ISP records and the magnitude of the EPS surprise. ^[13]

Management color & balance sheet

CEO Glenn Williams said results reflected “solid and consistent performance across all segments,” pointing to strength in ISP and steady Term Life premiums—framing the quarter as validation of the firm’s complementary business mix focused on middle‑income families. Primerica also underscored ROE of 35.9% and adjusted operating ROAE of 36.2%, alongside the Q3 $129M buyback and the $1.04 dividend declaration. ^[14]

What to watch on today’s call (Nov. 6, 10:00 a.m. ET)

Life productivity & policy trends: With productivity at 0.17 and policies issued −15% YoY, any commentary on recruiting efficiency and conversion could shape near‑term Term Life growth. ^[15]
ISP sales mix & pricing: Continued mix shift toward variable annuities and managed accounts helped outpace asset growth; details on sustainability and seasonality matter into Q4. ^[16]
Claims dynamics: The benefits & claims ratio at 54.9% edged up; drivers and outlook will be key for margins. ^[17]
Capital deployment: Follow‑through on buybacks/dividends and capital intensity given an estimated ~515% RBC ratio. ^[18]

Webcast details and materials are posted on the company’s investor relations site (release, financial supplement, and audio stream). ^[19]

By the numbers (Q3 2025)

Revenue: $839.9M (+8% YoY)
GAAP EPS: $6.35; Adjusted EPS: $6.33 (+11% YoY)
Term Life adjusted direct premiums: +5% YoY
ISP sales: $3.7B (record, +28% YoY)
Average client asset values: $123.1B (+14% YoY); quarter‑end $126.8B (record)
Life‑licensed sales force: 152,200 (+2% YoY)
Share repurchases: $129M; Dividend: $1.04 (payable Dec. 15; record Nov. 21)
ROE/ROAE: 35.9% / 36.2%
Remeasurement gain: $23.1M (~$0.54 per share)
All figures company‑reported. ^[20]

Context for investors

Expectation bar: Consensus heading into the print was for $5.53 EPS and ~$823–825M revenue; Primerica cleared both, with third‑party trackers citing a ~+14.7% EPS and ~+1.4% revenue upside. ^[21]
Early share move: Initial after‑hours trading tilted positive, though live pricing today shows consolidation as the market absorbs segment mix and actuarial gains. ^[22]

Sources cited today (Nov. 6, 2025)

Company press release & IR materials; Zacks/Yahoo Finance post‑earnings recap; Reuters/LSEG preview; additional third‑party recaps for context and market reaction. ^[23]

Editorial note: This article is for information only and not investment advice. Always do your own research or consult a licensed adviser.

How much does the average Primerica agent make per-year (according to #Primerica)

Watch this video on YouTube.

References

Tags:

Marcin Frąckiewicz Latest posts

CEO of TS2 Space and founder of TS2.tech. Expert in satellites, telecommunications, and emerging technologies, covering trends in space, AI, and connectivity.

View all

Is Elevance Health a Hidden Opportunity After a 24.5% Drop in 2025?
November 6, 2025, 7:28 AM EST. Elevance Health has tumbled in 2025 amid policy shifts and broader healthcare-sector volatility, with a year-to-date drawdown and a longer 24.5% slide that has investors rethinking value. The piece weighs near- and long-term catalysts, noting that a high valuation score isn't translating into certainty as government program changes loom for managed care. The core takeaway is a rigorous DCF assessment, which, using current free cash flow of $3.6B and projected growth, yields an intrinsic value around $1,090.84 per share-roughly 71% above current prices, signaling undervaluation. Still, equity investors should monitor the PE ratio, competitive dynamics, and policy risk, which could affect how quickly this perceived bargain translates into realized gains.
Inflammation Biotech Evommune Starts NYSE Trading in $150M IPO
November 6, 2025, 7:24 AM EST. Evommune is heading to the NYSE with a $150 million IPO to fund two clinical-stage assets. The Palo Alto biopharma is offering 9.3 million shares at $16 each, pricing in the $15-$17 range. Gross proceeds are $150 million, potentially rising by about $22.5 million if underwriters exercise their option for an additional 1.4 million shares. Trading under the ticker EVMN could begin today. The company plans to use the funds to advance two phase 2 programs, including EVO756, an oral MRGPRX2 antagonist being studied for CSU and atopic dermatitis (AD). Topline data for CSU from a phase 2 study showed 93% responses at four weeks. Data for AD topline in H2 2026. Evommune priced amid a broader biotech IPO backdrop as MapLight Therapeutics went public last week.
Arm Holdings Stock Surges on Q2 Beat, Strong AI Demand Lifts Outlook
November 6, 2025, 7:22 AM EST. Arm Holdings (ARM) stock jumps about 5-6% in pre-market trading after reporting a Q2 beat that topped revenue and earnings estimates and issuing stronger Q3 guidance. The company posted revenue of $1.14 billion, up 34% year over year, and EPS of $0.22, exceeds consensus of $0.13. Arm also raised its quarterly revenue guide to about $1.23 billion versus the $1.10 billion expected. Royalty revenue reached a record $620 million, up 21%, led by data centers, automotive, and IoT, with hyperscalers like Google, Amazon, and Microsoft boosting Arm-based deployments. Licensing revenue rose 56% to $515 million. The AI infrastructure buildout underscores demand for Arm's energy-efficient designs, and management hints at potential in-house chip development beyond licensing.
Capital One Stock Prediction: Analysts See Up to 29% Upside by 2027 on Discover Acquisition
November 6, 2025, 7:20 AM EST. Capital One (NYSE: COF) trades around $221 with an average target near $260, implying ~18% upside. Targets span $290 (high) and $210 (low), with a median near $258 and a mix of 14 Buys, 3 Outperforms, and 6 Holds. Growth projections call for revenue up about 19% annually through 2027, supported by operating margins near 48% and a forward multiple around 9.7x. A guided model points to ~$285/share by 2027, or about 29% total upside (12% annualized). The story centers on the Discover acquisition, expanded payments network, and stable credit trends amid solid consumer spending, though conviction remains modest and upside depends on continued earnings growth and credit stability.
Three Stocks Added to Zacks Rank #5 Strong Sell List on Nov. 6: ACHC, FWRD, CENX
November 6, 2025, 7:18 AM EST. Three names were added to Zacks Rank #5 (Strong Sell) today: Acadia Healthcare (ACHC), Forward Air (FWRD), and Century Aluminum (CENX). For the current year, earnings estimates were revised downward by 3.2%, 12%, and 11.7% over the last 60 days, respectively. The update reinforces the Strong Sell roster per Zacks research. The piece also highlights a separate feature on a stock most likely to double and a prompt to download Zacks' top stock ideas.